- Home
- CTW vs GNLX Comparison
CTW vs GNLX Comparison
Compare CTW & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTW | GNLX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 133.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CTW | GNLX |
|---|---|---|
| Price | $2.33 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 22.4K | ★ 159.8K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $2.29 |
| 52 Week High | $3.14 | $8.54 |
Technical Indicators
Market Signals| Indicator | CTW | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 52.68 |
| Support Level | $1.98 | $2.74 |
| Resistance Level | $2.51 | $3.16 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 34.72 | 73.31 |
Price Performance
Historical ComparisonAbout CTW CTW Cayman Class A Ordinary Shares
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.